Core Viewpoint - The A-share market is witnessing a surge in major asset restructuring activities, with significant transactions announced by companies like Dongxing Medical and Fuda Alloy, indicating a revitalization of the M&A landscape following regulatory changes [2][5][9]. Group 1: Dongxing Medical - Dongxing Medical announced plans to acquire 90% of Wuhan Yijiaobao Biological Materials Co., Ltd. for cash, which is expected to constitute a major asset restructuring [2][3]. - The acquisition aligns with Dongxing Medical's strategic business development needs and aims to enhance its capabilities in the surgical medical device sector, particularly in synthetic biology [5][6]. - The transaction is still in the preliminary planning stage, with a share purchase intention agreement signed, but final terms are yet to be negotiated [5][6]. Group 2: Fuda Alloy - Fuda Alloy plans to acquire 52.61% of Zhejiang Guangda Electronic Technology Co., Ltd. for 352 million yuan, which will make it the controlling shareholder [9][10]. - The acquisition is part of Fuda Alloy's strategy to diversify its product offerings in the electronic materials sector, particularly in electronic paste products [9][10]. - Guangda Electronic has shown strong revenue growth, with projected revenues of 1.65 billion yuan in 2023 and 2.68 billion yuan in 2024, indicating a promising outlook for the acquired business [10].

Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which will become a subsidiary if the transaction is successful, aligning with the company's strategic business development needs [3][4][5]. Group 1: Acquisition Details - The acquisition will be conducted through cash payment, and the final terms, including the equity ratio and transaction price, are still under negotiation [5]. - The transaction is expected to constitute a major asset restructuring as defined by the regulations, but it will not change the controlling shareholder or actual controller of Dongxing Medical [5][6]. - Dongxing Medical focuses on the research, production, and sales of surgical medical devices, while Wuhan Yijiaobao specializes in high-end orthopedic and biomedical materials [5][6]. Group 2: Strategic Rationale - The acquisition is a strategic decision aimed at integrating high-quality industry resources and expanding the company's surgical medical device supply chain [6]. - The deal is anticipated to enhance the company's overall strength and positively impact future business development and operational performance [6]. Group 3: Company Background - As of September 26, Dongxing Medical's stock price was 27.96 yuan per share, with a market capitalization of approximately 2.8 billion yuan [8]. - The company has around 10,400 shareholders [8].